Axicabtagene ciloleucel - Biologic Drug Details

Summary for axicabtagene ciloleucel

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for axicabtagene ciloleucel

Recent Clinical Trials for axicabtagene ciloleucel

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Southwest Oncology Group	Phase 2
Stichting Hemato-Oncologie voor Volwassenen Nederland	Phase 2
University Medical Center Groningen	Phase 2

See all axicabtagene ciloleucel clinical trials

Pharmacology for axicabtagene ciloleucel

Mechanism of Action	CD19 Receptor Interactions
Physiological Effect	Increased T Lymphocyte Activation
Established Pharmacologic Class	CD19-directed Chimeric Antigen Receptor Genetically-modified Autologous T Cells
Chemical Structure	CD19-specific Chimeric Antigen Receptor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for axicabtagene ciloleucel Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for axicabtagene ciloleucel Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for axicabtagene ciloleucel Derived from Patent Text Search

No patents found based on company disclosures